Recent findings suggest that microRNA-26a (miRNA-26a) suppresses tumour angiogenesis in hepatocellular carcinoma (HCC) by inhibiting hepatocyte growth factor (HGF)–HGF receptor (cMet) signalling, revealing a potential new therapeutic target.
Lun-Xiu Qin (Fudan University, China) and colleagues had previously shown that miRNA-26a suppresses tumour growth and metastasis in HCC. These findings led the team to investigate whether miRNA-26a was also involved in tumour angiogenesis.